Stroke

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 10, 2021.

While typically thought of as a disease that affects younger populations, Rebecca O’Dwyer, MD, stressed the importance and nuances of caring for older adults with epilepsy.

Here's what is coming soon to NeurologyLive®.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Data suggest that roughly 1 in 100 patients hospitalized with COVID-19 infection will develop central nervous system complications.

The investigational ZZ Biotech treatment was previously evaluated in patients with acute ischemic stroke, with exploratory analyses showing a trend towards lower hemorrhage rate.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 3, 2021.

Expert clinicians offer their perspectives on transitional care in pediatric MS, a biomarker for SUDEP, and a novel approach to narcolepsy, among other topics.

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 26, 2021.

The assistant professor of neurology at Weill Cornell Medicine discussed his future aspirations to uncover more about the beneficial effects of anticoagulants in reducing recurrent stroke. [WATCH TIME: 3 minutes]

The risk of dementia was substantial and front-loaded following stroke, with the 1-year prevalence similar to the estimate for dementia at any time point. The findings indicate a need for greater engagement between stroke and dementia care.

The optimal range of HbA1c between 6.8% and 7.0% at admission was estimated to have the minimum risk for composite vascular events and stroke recurrence, with notably different levels according to stroke subtype.

Here's what is coming soon to NeurologyLive®.

Neurology News Network for the week ending November 20, 2021.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 19, 2021.

The long-term benefits observed were due to maintenance of the early effect, rather than any additional benefit accrued after 90 days of the initial event, with no evidence either of rebound or loss of benefit.

The assistant professor of neurology at Weill Cornell Medicine provided thoughts on the need to identify high-risk individuals and put efforts towards improving recurrent stroke rates. [WATCH TIME: 2 minutes]

Here's what is coming soon to NeurologyLive.

Even after adjusting to traditional stroke risk factors, the associations between clonal hematopoiesis and all stroke types, ischemic stroke, and hemorrhagic stroke remained significant.

Having previously served as head of the organization during the Obama administration, Califf will replace current Acting Commissioner Janet Woodcock, MD.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 12, 2021.

The assistant professor of neurology at Weill Cornell Medicine discussed the results of the NAVIGATE-ESUS trial and whether stroke experts should change how they use anticoagulants.

The assistant professor of neurology at Weill Cornell Medicine provided thoughts on his exploratory analysis, which found rivaroxaban to be superior to aspirin in reducing recurrent stroke.